NDA 020637 · Azurity
Gliadel
Carmustine · Intracranial · Alkylating Drug
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 5, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Sep 23, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
259
44 Phase 3, 18 recruiting
FAERS reports
4,717
4,619 serious, 1,214 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 5, 2024.
GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated for the treatment of: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation ( 1 ) and recurrent glioblastoma as an adjunct to surgery ( 1 )
Mechanism: The activity of GLIADEL Wafer is due to release of cytotoxic concentrations of carmustine, a DNA and RNA alkylating agent, into the tumor resection cavity. On exposure to the aqueous environment of the resection cavity, the anhydride bonds in the copolymer are hydrolyzed, releasing carmustine, carboxyphenoxypropane, and sebacic acid into the surrounding brain tissue.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 25, 2003 Supplement 16 · Efficacy · priority review ReviewLetterLabel
- Sep 23, 1996 Original approval · Type 3 - New Dosage Form · priority review Review
1 products under this application
- GLIADEL · CARMUSTINE 7.7MG · IMPLANT, INTRACRANIAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Carmustine" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple MyelomaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002653 · 1,000 participants (planned) · Start Sep 1993
Drug: carmustine; cyclophosphamide and 3 more · For: Multiple Myeloma and Plasma Cell Neoplasm
Sites: Birmingham, United Kingdom
- SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated MyelomaPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00002548 · 899 participants · Start Jan 1994 · Primary completion Oct 2003
Drug: recombinant interferon alfa; carmustine and 6 more · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Denver, Colorado; Tampa, Florida · 34 sites in all
- Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With MyelomaPivotal-lookingStatus unknown
Medical Research CouncilGovernment (non-federal)
NCT00002599 · 750 participants (planned) · Start Sep 1994
Drug: filgrastim; recombinant interferon alfa and 8 more · For: Multiple Myeloma and Plasma Cell Neoplasm
Sites: Leeds, United Kingdom
- Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant GliomaPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT03722355 · 712 participants · Start Nov 9, 1990 · Primary completion Mar 15, 1994
Drug: Carmustine · For: Glioma; Glioblastoma Multiforme; Astrocytoma
- UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation ChemotherapyPivotal-lookingCompleted
University of ArkansasAcademic, hospital or other
NCT00083551 · 668 participants · Start Aug 1998 · Primary completion Aug 2014
Drug: Thalidomide; Ara-C and 11 more · For: Multiple Myeloma
Sites: Little Rock, Arkansas
- S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast CancerPivotal-lookingTerminated
SWOG Cancer Research NetworkResearch network
NCT00002772 · 602 participants · Start Jul 1996 · Primary completion Feb 2004
Drug: filgrastim; carboplatin and 7 more · For: Breast Cancer
Sites: New York, New York
- Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid LeukemiaPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00002719 · 500 participants (planned) · Start Dec 1995 · Primary completion Nov 2001
Drug: filgrastim; amsacrine and 5 more · For: Leukemia; Neutropenia
Sites: Rome, Italy
- High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's LymphomaPivotal-lookingStatus unknown
Lymphoma Trials OfficeAcademic, hospital or other
NCT00003578 · 500 participants (planned) · Start Jan 1993
Drug: CHOP regimen; carmustine and 7 more · For: Lymphoma
Sites: Prague (Praha), Czechia; Aarhus, Denmark; Copenhagen, Denmark · 72 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use521
- febrile neutropenia400
- myelodysplastic syndrome301
- disease progression292
- mucosal inflammation256
- thrombocytopenia252
- pyrexia242
- neutropenia211
- pneumonia206
- drug ineffective202
- infection183
- acute myeloid leukaemia172
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 92 |
| 2005 | 112 |
| 2006 | 105 |
| 2007 | 118 |
| 2008 | 134 |
| 2009 | 103 |
| 2010 | 90 |
| 2011 | 147 |
| 2012 | 144 |
| 2013 | 139 |
| 2014 | 101 |
| 2015 | 194 |
| 2016 | 126 |
| 2017 | 247 |
| 2018 | 337 |
| 2019 | 351 |
| 2020 | 375 |
| 2021 | 311 |
| 2022 | 292 |
| 2023 | 440 |
| 2024 | 298 |
| 2025 | 229 |
| 2026 | 232 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, et al. · Pharmacol Res 2021 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, et al. · Leukemia 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
Batchelor TT, Giri S, Ruppert AS, et al. · Blood Adv 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- Vincristine in high-grade glioma.
Aydin B, Patil M, Bekele N, et al. · Anticancer Res 2010 · Meta-Analysis
- Megestrol melanoma study.
Nathanson L, Garrison M · World J Surg 1995 · Clinical Trial
- Chemotherapy wafers for high grade glioma.
Hart MG, Grant R, Garside R, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.